Wolfe Research analyst Andy Chen downgraded Akero Therapeutics (AKRO) to Peer Perform from Outperform following Novo Nordisk’s (NVO) plan to acquire Akero for $4.7B upfront, equivalent to about $54 per share.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Akero Therapeutics rises 16.6%
- Midday Fly By: Delta beats, PepsiCo names new CFO
- Akero downgraded to Market Perform from Outperform at LifeSci Capital
- Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties